Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved?

The Lancet Neurology

Volumn 13, Issue 11, 2014, Pages 1127-1138

  Mitsumoto, Hiroshi ^a   Brooks, Benjamin R ^b   Silani, Vincenzo ^c  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARIMOCLOMOL; CREATININE; DEXPRAMIPEXOLE; DEXTROMETHORPHAN PLUS QUINIDINE; LITHIUM; NEW DRUG; RILUZOLE; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BRAIN ELECTROPHYSIOLOGY; EVIDENCE BASED MEDICINE; HUMAN; LEUKOCYTE COUNT; MEDICAL DEVICE; MODIFIER GENE; MUSCLE STRENGTH; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; NONINVASIVE VENTILATION; OXIDATIVE STRESS; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; STUDY DESIGN; STANDARDS; TRENDS;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RILUZOLE; STEM CELL TRANSPLANTATION;

EID: 84907984891     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70129-2     Document Type: Review

References (106)

1. Considerations regarding Food and Drug Administration review and regulation of drugs for the treatment of amyotrophic lateral sclerosis US Food and Drug Administration, (accessed May 4, 2014). http://www.fda.gov/Drugs/NewsEvents/ucm339833.htm.
2. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS) European Medicines Agency, (accessed May 4, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147005.pdf.
3. Brooks BR El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology research group on neuromuscular diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994, 124(suppl):96-107.
4. Brooks BR, Miller RG, Swash M, Munsat TL El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:293-299. World Federation of Neurology research group on motor neuron diseases.
5. World Federation of Neurology Research Group on Motor Neuron Diseases, (accessed May 4, 2014). http://www.wfnals.org/index.html.
6. Miller RG, Munsat TL, Swash M, Brooks BR Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci 1999, 169:2-12.
7. Rothstein JD, Martin LJ, Kuncl RW Decreased glutamate transport by the brain and spinal-cord in amyotrophic lateral sclerosis. N Engl J Med 1992, 326:1464-1468.
8. Heath PR, Shaw PJ Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:438-458.
9. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
10. Vandenberghe W, Robberecht W, Brorson JR AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J Neurosci 2000, 20:123-132.
11. Bradley WG Critical-review of gangliosides and thyrotropin-releasing-hormone in peripheral neuromuscular diseases. Muscle Nerve 1990, 13:833-842.
12. Mitsumoto H, Tsuzaka K Neurotrophic factors and neuromuscular disease: I.General comments, the neurotrophin family, and neuropoietic cytokines. Muscle Nerve 1999, 22:983-999.
13. Philips T, Robberecht W Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011, 10:253-263.
14. Smith RG, Siklos L, Alexianu ME, et al. Autoimmunity and ALS. Neurology 1996, 47(suppl 2):S40-S45.
15. Barber SC, Shaw PJ Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010, 48:629-641.
16. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013, 65:509-527.
17. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008, 105:16404-16407.
18. Kieran D, Kalmar B, Dick JRT, Riddoch-Contreras J, Burnstock G, Greensmith L Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004, 10:402-405.
19. Habib AA, Mitsumoto H Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 2011, 16:537-558.
20. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013, 12:310-322.
21. DiMasi JA, Feldman L, Seckler A, Wilson A Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010, 87:272-277.
22. Meininger V, Bensimon G, Bradley WG, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004, 5:107-117.
23. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004, 63:1656-1661.
24. Rosenfeld J, King RM, Jackson CE, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler 2008, 9:266-272.
25. Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005, 112:649-660.
26. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006, 60:22-31.
27. Meininger V, Asselain B, Leigh PN, Ludolph A, Lacomblez L, Guillet P Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial-reply. Neurology 2006, 66:1786-1787.
28. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
29. Milane A, Tortolano L, Fernandez C, Bensimon G, Meininger V, Farinotti R Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J Pharm Pharm Sci 2009, 12:209-217.
30. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007, 69:776-784.
31. Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
32. Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009, 66:235-244.
33. Lauria GBG, Capasso M, Caponnetto C, et al. Efficacy of erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double-blind, placebo-controlled, phase III study (EPOS trial). Amyotroph Lateral Scler Frontotemporal Degener 2009, 10:410-415.
34. Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009, 10:378-383.
35. Mosley RL, Gordon PH, Hasiak CM, Van Wetering FJ, Mitsumoto H, Gendelman HE Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotroph Lateral Scler 2007, 8:235-242.
36. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:481-488.
37. Chio A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010, 75:619-625.
38. Miller RG, Moore DH, Forshew DA, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 2011, 77:973-979.
39. Verstraete E, Veldink JH, Huisman MHB, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosur Psychiatry 2012, 83:557-564.
40. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013, 12:339-345. UKMND-LiCALS Study Group.
41. Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:266-271.
42. Dupuis L, Dengler R, Heneka MT, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 2012, 7:e37885.
43. Berry JD, Shefner JM, Conwit R, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013, 8:e61177.
44. Beghi E, Pupillo E, Bonito V, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14:397-405.
45. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013, 12:1059-1067.
46. Bozik MMH, Brooks B, Rudnicki S, et al. A post-hoc analysis of subgroup outcomes and biomarkers in the phase 3 clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014, 15:406-413.
47. Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 2014, 21:529-536.
48. Rothstein JD Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol 2003, 53:423-426.
49. Whitaker JN Current status of thyrotropin-releasing-hormone therapy in amyotrophic-lateral-sclerosis. Ann Neurol 1987, 22:541-543.
50. Gurney ME, Cutting FB, Zhai P Therapeutic benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis (FALS). Amyotroph Lateral Scler 1996, 1104:322-330.
51. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999, 5:347-350.
52. Meininger V, Shefner J, Cudkowicz M Lithium therapy in ALS. Amyotroph Lateral Scler 2008, 9:122.
53. Figlewicz DA Comments on Fornai et al. (PNAS/Feb 2008). Amyotroph Lateral Scler 2008, 9:125-126.
54. Gill A, Kidd J, Vieira F, Thompson K, Perrin S No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 2009, 4:e6489.
55. Pizzasegola C, Caron I, Daleno C, et al. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 2009, 10:221-228.
56. Wicks P, Vaughan TE, Massagli MP, Heywood J Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol 2011, 29:411-414.
57. Sipp D The unregulated commercialization of stem cell treatments: a global perspective. Front Med 2011, 5:348-355.
58. Chew S, Khandji AG, Montes J, Mitsumoto H, Gordon PH Olfactory ensheathing glia injections in Beijing: misleading patients with ALS. Amyotroph Lateral Scler 2007, 8:314-316.
59. Piepers S, van den Berg LH No benefits from experimental treatment with olfactory ensheathing cells in patients with ALS. Amyotroph Lateral Scler 2010, 11:328-330.
60. Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol 2010, 223:229-237.
61. Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014, 75:363-373.
62. Riley J, Federici T, Polak M, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery 2012, 71:405-416.
63. Cova L, Silani V Amyotrophic lateral sclerosis: applications of stem cells-an update. Stem Cells Cloning 2010, 3:145-156.
64. Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006, 66:660-663.
65. Scelsa SN, MacGowan DJ, Mitsumoto H, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology 2005, 64:1298-1300.
66. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler 2005, 6:37-44.
67. Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 2010, 11:38-45.
68. Collins FS, Tabak LA NIH plans to enhance reproducibility. Nature 2014, 505:612-613.
69. Benatar M, Polak M, Kaplan S, Glass J Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible?. J Neurol Sci 2006, 251:3-9.
70. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013, 12:435-442.
71. Beghi E, Chio A, Couratier P, et al. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 2011, 12:1-10.
72. Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosur Psychiatry 2011, 82:628-634.
73. Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009, 10:310-323.
74. de Carvalho M, Swash M Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?. Arch Neurol-Chicago 2006, 63:557-560.
75. Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosur Psychiatry 2013, 84:163-169.
76. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011, 76:1263-1269.
77. Sobue G, Sahashi K, Takahashi A, Matsuoka Y, Muroga T, Sobue I Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss. Neurology 1983, 33:654-657.
78. Zoccolella S, Beghi E, Palagano G, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci 2006, 250:45-49.
79. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008, 119:497-503.
80. Krarup C Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis. Clin Neurophysiol 2011, 122:414-422.
81. Eisen A, Kiernan M, Mitsumoto H, Swash M Amyotrophic lateral sclerosis: a long preclinical period. J Neurol Neurosurg Psychiatry 2014, published online March 19. 10.1136/jnnp-2013-307135.
82. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994, 330:585-591.
83. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-2194.
84. Shefner JM, Leigh N Commentary on 'A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS'. Amyotroph Lateral Scler 2008, 9:254-256.
85. Weiss MD, Weydt P, Carter GT Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy. Expert Opin Pharmacother 2004, 5:735-746.
86. Gordon PH, Cheung YK, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008, 9:212-222.
87. Devita VT, Young RC, Canellos GP Combination versus single agent chemotherapy-review of basis for selection of drug treatment of cancer. Cancer 1975, 35:98-110.
88. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003, 53:437-445.
89. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009, 66:184-190.
90. Using social networking to bring patients, clinicians and scientists together for investigation of alternative or off-label ALS treatment ALS Untangled, (accessed May 4, 2014). http://www.alsuntangled.com.
91. Lee A, Patterson V A double-blind-study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993, 88:334-338.
92. Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ Noninvasive ventilation in ALS-indications and effect on quality of life. Neurology 2003, 61:171-177.
93. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine-a randomized trial. Neurology 2004, 63:1364-1370.
94. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010, 68:693-702.
95. Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS-an exploratory randomized, controlled trial. Neurology 2006, 67:991-997.
96. Sato Y, Honda Y, Iwamoto J Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial. Bone 2006, 39:1080-1086.
97. Dal Bello-Haas V, Florence JM, Kloos AD, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 2007, 68:2003-2007.
98. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve 2009, 39:297-303.
99. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009, 39:137-143.
100. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Movement Disord 2011, 26:313-319.
101. van Groenestijn AC, van de Port IG, Schroder CD, et al. Effects of aerobic exercise therapy and cognitive behavioural therapy on functioning and quality of life in amyotrophic lateral sclerosis: protocol of the FACTS-2-ALS trial. BMC Neurol 2011, 11:70.
102. Shefner JM, Watson ML, Meng L, Wolff AA A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14:574-581. Neals/Cytokinetics study team.
103. Dorst J, Cypionka J, Ludolph AC High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14:533-536.
104. Wills A-M, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014, published online Feb 28. http://dx.doi.org/10.1016/S0140-6736(14)60222-1.
105. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009, 73:1227-1233.
106. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009, 73:1218-1226.